|
Sacituzumab Govitecan (SG) Clinical Trials
8 actively recruiting trials across 5 locations
No change since May 2026
Also known as: GS-0132, IMMU 132, IMMU-132, Sacituzumab Govitecan-hziy, Trodelvy +1 more
Pipeline
Phase 2: 1Phase 3: 1Phase 1/2: 3Phase 2/3: 1
Top Sponsors
- Peking University Cancer Hospital & Institute2
- Yale University1
- University of California, Irvine1
- University Hospital Heidelberg1
- Marengo Therapeutics, Inc.1
Indications
- Cancer8
- Breast Cancer4
- Trop21
- Brain Metastases From Breast Cancer1
- Triple Negative Locally Advanced Non-resectable Breast Cancer1
Other3 trials
Hot Springs, Arkansas1 trial
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Genesis Cancer and Blood Institute
Phase 3
Los Angeles, California1 trial
Orange, California1 trial
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Chao Family Comprehensive Cancer Center, University of California, Irvine
Phase 2
New Haven, Connecticut1 trial
Saci Nivo Rela for TNBC
Yale University
Phase 1/2
Boston, Massachusetts1 trial
Sacituzumab Govitecan Plus EV in Metastatic UC
Dana Farber Cancer Institute
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.